Unilife Corporation Announces Financial Results For Fiscal Year 2012 Third Quarter

YORK, Pa., April 26, 2012 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS; ASX: UNS) today announced financial results for the quarter ended March 31, 2012 (the third quarter of Fiscal Year 2012).

Recent Highlights:

  • Supplying pharmaceutical companies with shipments of the Unifill ready-to-fill (prefilled) syringe.
  • Further expansion of the Unilife AutoInfusor platform of wearable, disposable pumps for the self-administration of large-volume dose. Supplied devices to multiple pharmaceutical companies for evaluation and user studies during the March Quarter, with favorable results.
  • Successful development of Unilife's first specialized device for targeted organ delivery, which is ready for supply to a global pharmaceutical customer for use in human clinical drug trials scheduled to occur later this year. Unilife recognized revenue of $566,000 during the March Quarter as part of the initial stage of this program.
  • Continuing positive developments with pharmaceutical customers for other proprietary devices including the EZMix dual chamber prefilled syringe and Rita Auto-Injector.
  • Sponsorship of Safe in Common's Needlestick Safety Advocacy Tour.
  • Successful Analyst and Shareholder Day held in New York in March 2012.
  • Unilife CEO Alan Shortall completed open market purchases of the Company's common stock totaling approximately $1.0 million from January to February of 2012.

Unilife CEO Alan Shortall commented, "Unilife remains fully on track to deliver upon several key business milestones this year. We look forward to driving future shareholder value by building partnerships with our expanding network of pharmaceutical customers, accelerating the commercialization of our diversified portfolio of advanced drug delivery systems, and expanding our production capabilities.

"Unilife continues to supply the Unifill prefilled syringe to current and new pharmaceutical customers. We look forward to the signing of commercial supply contracts for Unifill, which we anticipate throughout the second half of 2012.

"We have aggressively increased our investment in R&D, as well as existing production capacities in anticipation of several new development and supply agreements that we expect to secure starting in the second half of 2012. Our increase in R&D has already generated many positive developments.

"For example, I am pleased to advise that the first GMP-compliant batch of our specialized device for targeted organ delivery is now ready to be shipped to a global pharmaceutical company for use in human clinical drug trials scheduled to occur later this year. To date, we have recognized revenue of approximately $800,000 for this program and expect to recognize the balance of this $1.4M initial stage in the next quarter. We further expect to generate additional revenues as this program continues to move forward.

"In addition, our platform of wearable, disposable AutoInfusors for the subcutaneous self-administration of large volume doses is expanding rapidly in response to accelerating customer demands. Variants of our AutoInfusor technologies were supplied to several pharmaceutical companies during the March Quarter for market evaluations and user studies, with favorable outcomes, resulting in advancing our relationships to the next stages toward human clinical trials.

"We also continue to generate positive developments regarding other proprietary devices within our expanding proprietary portfolio, such as the EZMix dual chamber prefilled syringe and the Rita Auto-Injector. These investments in R&D reflect strong commercial interest from multiple pharmaceutical customers regarding the Unifill syringe and all other technology platforms within our rapidly expanding device portfolio.

"Given our confidence in our commercial pipeline to generate additional revenues from a number of sources, we are comfortable with the Company's cash position and ability to support current fixed costs for at least the next year," concluded Mr. Shortall.  

Financial Results for Three Months Ended March 31, 2012

Revenues for the three months ended March 31, 2012 were $1.3 million compared to $0.7 million for the same period in 2011.  During the three months ended March 31, 2012, the Company recognized revenue of $0.6 million related to the clinical development and supply of a novel device for targeted organ delivery.  

The Company's net loss for the three months ended March 31, 2012 was $14.9 million, or $0.21 per diluted share, compared to a net loss of $12.5 million, or $0.20 per diluted share, for the same period in 2011.  The increase in the net loss was primarily attributable to an increase in research and development expenses related to the development of additional advanced drug delivery devices. These amounts were partially offset by a reduction of $1.4 million in selling, general and administrative expenses. 

Adjusted net loss for the three months ended March 31, 2012 was $10.7 million, or $0.15 per diluted share, compared to $9.3 million, or $0.15 per diluted share, for the same period in 2011. Adjusted net loss excludes non-cash share-based compensation expense, depreciation and amortization and interest expense.

As of March 31, 2012, the Company's cash position was $27.2 million.

Conference Call Information

Management has scheduled a conference call for 4:30 p.m. U.S. Eastern Daylight Time on April 26, 2012, to review the Company's financial results, market trends and future outlook.  The conference call and accompanying slide presentation will be broadcast over the Internet as a "live" listen only Webcast.  An archive of the presentation and webcast will be available for 30 days after the call.  To listen, please go to: http://ir.unilife.com/events.cfm.

About Unilife Corporation

Unilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of advanced drug delivery systems. Unilife collaborates with pharmaceutical and biotechnology companies seeking innovative, differentiated devices that can enable or enhance the delivery of injectable drugs and vaccines supplied in either a liquid stable or lyophilized form. The Unifill syringe, the world's first and only prefilled syringe with fully integrated safety features, sits at the leading edge of this diversified portfolio. In addition to prefilled and hypodermic safety syringes with automatic, user-controlled needle retraction, Unilife has other proprietary technology platforms including drug reconstitution delivery systems, auto-injectors, auto-infusion pump systems and specialized devices for targeted organ delivery. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information on Unilife, please visit www.unilife.com   

Forward-Looking Statements

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission. 

Non-GAAP Financial Measures

U.S. securities laws require that when we publish any non-GAAP financial measure, we disclose the reason for using the non-GAAP measure and provide reconciliation to the most directly comparable GAAP measure.  The presentation of adjusted net income (loss) and adjusted net income (loss) per share are non-GAAP measures.  Adjusted net income (loss) represents net income (loss) calculated in accordance with U.S. GAAP as adjusted for the impact of share-based compensation expense, depreciation and amortization and interest expense.

Management believes the presentation of adjusted net income (loss) and adjusted net income (loss) per share provides useful information because these measures enhance its own evaluation, as well as investor's understanding, of the Company's core operating and financial results.  Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results.  A reconciliation of net income (loss) to adjusted net income (loss) is included in the attached table.

General: UNIS-G

Investor Contacts (US):            

Analyst Enquiries        

Investor Contacts (Australia)

Todd Fromer / Garth Russell       

Lynn Pieper                 

Jeff Carter

KCSA Strategic Communications 

Westwicke Partners    

Unilife Corporation

P: + 1 212-682-6300                     

P: + 1 415-202-5678  

P: + 61 2 8346 6500

(Tables Below)

 

UNILIFE CORPORATION AND SUBSIDIARIES

Consolidated Balance Sheets

(unaudited)






March 31, 2012


June 30, 2011


(in thousands, except share data)

Assets




Current Assets:




Cash and cash equivalents

$                          24,796


$                          17,910

Restricted cash

2,400


2,400

Accounts receivable

371


13

Inventories

618


626

Prepaid expenses and other current assets

876


381

Total current assets

29,061


21,330

Property, plant and equipment, net

53,336


54,020

Goodwill

13,009


13,265

Intangible assets, net

36


42

Other assets

1,293


821

Total assets

$                          96,735


$                          89,478

Liabilities and Stockholders' Equity




Current Liabilities:




Accounts payable

$                            2,686


$                            2,405

Accrued expenses

1,927


2,696

Current portion of long-term debt

5,503


2,274

Deferred revenue

2,652


2,706

Total current liabilities

12,768


10,081

Long-term debt, less current portion

24,557


20,413

Deferred revenue

3,315


5,412

Total liabilities

40,640


35,906

Stockholders' Equity:




Preferred stock, $0.01 par value, 50,000,000 shares authorized as of March 31, 2012;
  none issued or outstanding as of March 31, 2012 and June 30, 2011

-


-

Common stock, $0.01 par value, 250,000,000 shares authorized as of March 31, 2012;
  74,210,190 and 63,924,403 shares issued, and 74,181,520 and 63,905,053 shares
  outstanding as of March 31, 2012 and June 30, 2011, respectively

742


639

Additional paid-in-capital

209,695


169,590

Accumulated deficit

(157,773)


(120,332)

Accumulated other comprehensive income

3,571


3,775

Treasury stock, at cost, 28,670 and 19,350 shares as of March 31, 2012 and June 30, 2011, respectively

(140)


(100)

Total stockholders' equity

56,095


53,572

Total liabilities and stockholders' equity

$                          96,735


$                          89,478





 

 

UNILIFE CORPORATION AND SUBSIDIARIES

Consolidated Statements of Operations

(unaudited)










Three Months Ended
March 31,


Nine Months Ended
March 31,


2012


2011


2012


2011


(in thousands, except per share data)

Revenues:








Industrialization and development fees

$                 566


$                   -


$              2,255


$              1,350

Licensing fees

675


642


1,993


1,849

Product sales and other

10


8


45


2,756

Total revenues

1,251


650


4,293


5,955

Cost of product sales

18


450


108


2,449

Gross profit

1,233


200


4,185


3,506

Operating expenses:








Research and development

6,668


2,723


16,228


6,941

Selling, general and administrative

7,677


9,117


20,572


24,386

Depreciation and amortization

1,193


827


3,343


2,492

Total operating expenses

15,538


12,667


40,143


33,819

Operating loss

(14,305)


(12,467)


(35,958)


(30,313)

Interest expense

626


177


1,548


241

Interest income

(46)


(128)


(102)


(332)

Other expense (income), net

1


17


37


(85)

Net loss

$          (14,886)


$          (12,533)


$          (37,441)


$          (30,137)

Loss per share:








Basic and diluted loss per share

$              (0.21)


$              (0.20)


$              (0.57)


$              (0.53)

 

 

UNILIFE CORPORATION AND SUBSIDIARIES

Reconciliation of Non-GAAP Measure

(unaudited)










Three Months Ended
March 31,


Nine Months Ended
March 31,


2012


2011


2012


2011


(in thousands, except per share amounts)

Net loss

$          (14,886)


$          (12,533)


$          (37,441)


$          (30,137)

Share-based compensation expense

2,403


2,216


5,788


6,602

Depreciation and amortization

1,193


827


3,343


2,492

Interest expense

626


177


1,548


241

Adjusted net loss

$          (10,664)


$            (9,313)


$          (26,762)


$          (20,802)

Adjusted net loss per share - diluted

$              (0.15)


$              (0.15)


$              (0.40)


$              (0.37)









 

 


 

SOURCE Unilife Corporation



RELATED LINKS
http://www.unilife.com

More by this Source

View all news by Unilife Corporation

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.